Endocrine Abstracts

Immune-checkpoint inhibitors have been increasing used in the field of medical oncology for treatment of various early to late-stage malignancies, however, rare occurrences of adrenal insufficiency and thyroid dysfunction may occur. Pembrolizumab, a PD-1 inhibitor, has been associated with adrenal insufficiency in 1-2% of patients, while thyroid related adverse events occurred in 3.2-10.1%. This is a case report of an 81 year-old male, known to have a cutaneous melanoma stage ...